Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 24, Issue SUPPL.6, 2013, Pages

  Colombo, N ^a   Preti, E ^a   Landoni, F ^a   Carinelli, S ^a   Colombo, A ^b   Marini, C ^c   Sessa, C ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b A MANZONI HOSPITAL   (Italy)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; RIDAFOROLIMUS; TAMOXIFEN; TEMSIROLIMUS;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CARCINOMA; CLEAR CELL CARCINOMA; COMPUTER ASSISTED SURGERY; CYTOREDUCTIVE SURGERY; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; LAPAROSCOPY; LAPAROTOMY; LYMPH NODE DISSECTION; METASTASIS; MINIMALLY INVASIVE SURGERY; PARAAORTIC LYMPHADENECTOMY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; RISK ASSESSMENT; ROBOTICS; SALPINGOOOPHORECTOMY; SEROUS CARCINOMA; SYSTEMATIC PELVIC LYMPHADENECTOMY;

AGE FACTORS; AGING; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RISK; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84885354186     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt353     Document Type: Article

References (28)

1. http://globocan.iarc.fr. (12 July 2013, date last accessed).
2. Vergote I, Amant F, Timmerman D. Should we screen for endometrial cancer? Lancet Oncol 2011; 12: 4-5.
3. Timmerman A, Opmeer BC, Khan KS et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analisys. Obstet Gynecol 2010; 116: 160-167.
4. Clark TJ, Volt D, Gupta JK et al. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. J Am Med Assoc 2002; 288: 1610-1621.
5. Pecorelli S. FIGO Committee on Gynacologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105: 103-104.
6. Kinkel K, Kaji Y, Yu KK et al. Radiologic staging in patients with endometrial cancer: a meta analysis. Radiology 1999; 212: 711-718.
7. Sala E, Rockall A, Kubik-Huch RA. Advances in magnetic resonance imaging of endometrial cancer. Eur Radiol 2011; 21: 468-473.
8. Savelli L, Ceccarini M, Ludovisi M et al. Preoperative local staging of endometrial cancer: transvaginal sonography versus magnetic resonance imaging. Ultrasound Obstet Gynecol 2008; 31: 560-568.
9. Paley PJ, Veljovich DS, Shah CA. Surgical outcomes in gynecologic oncology in the era of robotics: analysis of first 1000 cases. Am J Obstet Gynecol 2011; 204: 551e1-5551e.
10. Benedetti PP, Basile S, Maneschi F et al. Systematic pelvic lymphadenectomy versus no lymphadenectomy in early-stage endometrial carcinoma: randomised clinical trial. J Natl Cancer Inst 2008; 100: 1707-1716.
11. ASTEC study group Kitchener H, Swart AM, Qian A et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ATEC trial): a randomised study. Lancet 2009; 373: 125-136.
12. Todo Y, Kato H, Kaneuchi M et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010; 375: 1165-1172.
13. Creutzberg CL, van Putten WL, Koper PC et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 2000; 355: 1404-1411.
14. Keys HM, Roberts JA, Brunetto VL et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 744-751.
15. Blake P, Swart AM, Orton J et al. ASTEC/EN.5 Study Group, Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and metaanalysis. Lancet 2009; 373: 137-146.
16. Nout RA, Smit VT, Putter H et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375: 816-823.
17. Maggi R, Lissoni A, Spina A et al. Adjuvant chemotherapy versus radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 2006; 95: 266-271.
18. Susumu N, Sagae S, Udagawa Y et al. Randomised phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008; 108: 226-233.
19. Hogberg T, Signorelli M, de Oliveira CF et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results form two randomised studies. Eur J Cancer 2010; 46: 2422-2431.
20. Randall ME, Filiaci VL, Muss H et al. Randomised phase III trial of wholeabdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2006; 24: 36-44.
21. Humber CE, Tierney JF, Symonds RP et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007; 18: 409-420.
22. Oza AM, Elit L, Tsao MS et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011; 29: 3278-3285.
23. Colombo N, McMeekin DS, Schwartz PE et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. BJC 2013; 108: 1021-1026.
24. Fader AN, Drake RD, O'Malley DM et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 2009; 115: 2119-2127.
25. Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: a 2000-2002 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-796.
26. Lewin SN, Herzog TJ, Barrena Medel LI et al. Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for uterine corpus cancer. Obstet Gynecol 2010; 116: 1141-1149.
27. Werner HMJ, Trovik J, Marcickiewicz J et al. Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. Gynecol Oncol 2012; 125: 103-108.
28. Creasman WT. New gynecologic cancer staging. Obstet Gynecol 1990; 75: 287-288.